Dr. Cooperstone is a pharmaceutical executive with more than 20 years of experience in drug development.
Prior to joining Gandeeva Therapeutics’ Board of Directors, Brenda Cooperstone held key leadership positions as Pfizer’s Chief Development Officer, Rare Diseases, as well as Site Head in Collegeville, PA. Dr. Cooperstone also held various leadership positions at Pfizer and Wyeth across different therapeutic areas from early to late-stage clinical development and global medical affairs. Dr. Cooperstone was a pediatric nephrologist at the Scottish Rite Children’s Medical Center, an immunology research fellow at the University of Pennsylvania’s Renal Electrolyte Section, and a clinical fellow in pediatric nephrology at Children’s Hospital of Philadelphia. Dr. Cooperstone earned her M.D. at McGill University and completed her clinical residency at the Montreal Children’s Hospital in pediatrics. Dr. Cooperstone also serves as an independent board member at Senti Biosciences.